Daniel K. Spiegelman

Co-Founder at Rapidscan Pharma Solutions, Inc.

Daniel K. Spiegelman

Daniel K. Spiegelman

Co-Founder at Rapidscan Pharma Solutions, Inc.

Overview

Career Highlights

BioMarin Pharmaceutical, Inc.
CV Therapeutics, Inc.
Filtini, Inc.

RelSci Relationships

3544

Number of Boards

14

Birthday

1959

Age

61

Relationships

View Relationship Details

RelSci Relationships are individuals Daniel K. Spiegelman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Louis G. Lange

Executive Chairman & Founder at Amygdala Neurosciences, Inc.

Relationship likelihood: Strong

Christopher S. Henney

Director at Prothena Biosciences, Inc.

Relationship likelihood: Strong

Brent K. Blackburn

Founder at Rapidscan Pharma Solutions, Inc.

Relationship likelihood: Strong

Ted Love

President & Chief Executive Officer at Global Blood Therapeutics, Inc.

Relationship likelihood: Strong

Gwen Fyfe

Former Vice President-BioOncology at Genentech, Inc.

Relationship likelihood: Strong

Mike Grey

Venture Partner at Pappas Capital LLC

Relationship likelihood: Strong

Peter J. Langecker

Executive Medical Director, Global Oncology at Clinipace, Inc.

Relationship likelihood: Strong

Dennis J. Henner

Chief Scientific Advisor at Clarus Ventures LLC

Relationship likelihood: Strong

Adrienne M MacMillan

Chief Financial Officer & Founder at Amygdala Neurosciences, Inc.

Relationship likelihood: Strong

Jean-Jacques Bienaimé

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

In The News

RelSci

November 24, 2020

Daniel K. Spiegelman is now serving in a new board position at Jiya Acquisition Corp.

PR Newswire

November 18, 2020

Jiya Acquisition Corp. Announces Pricing Of $100 Million Initial Public Offering

GlobeNewswire

October 15, 2020

Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests

ENP Newswire

September 16, 2020

-Tizona Appoints Christine O'Brien as Chief Executive Officer

RelSci

September 13, 2020

Daniel K. Spiegelman is now serving in a new board position at Opthea Ltd.

Paths to Daniel K. Spiegelman

Potential Connections via
Relationship Science

You

Daniel K. Spiegelman

Co-Founder at Rapidscan Pharma Solutions, Inc.

Education

B.A. in Economics

Stanford University

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

M.B.A.

Stanford University - Stanford Graduate School of Business

The Stanford Graduate School of Business has built an international reputation based on its innovative programs, which include: Two-year MBA Program, designed to educate business leaders One-year Stanford Sloan Master’s Program for mid-career executives PhD Program for future academics Executive Education programs for experienced managers Faculty research program Academic programs, including the two-year MBA, the 12-month Sloan Master's Program, and the PhD program, create a transformational student experience that reflects the tagline: Change lives. Change organizations. Change the world. Today the state-of-the-art Knight Management Center complex enables Stanford's innovative, globalized MBA curriculum, offering flexible classroom spaces for hands-on experiential learning small-group leadership labs, and team-based learning. It engages faculty and students across Stanford University, as well as alumni, global executives, and the broader world community.

Career History

Co-Founder

2009 - Current

Rapidscan Pharma Solutions, Inc.

Rapidscan Pharma Solutions, Inc. provides novel technologies for the diagnosis of disease. Its products include Regadenoson which acts as a stress agent used in the diagnosis and risk stratification of cardiovascular disease. The company was founded by Brent K. Blackburn, Daniel K. Spiegelman and Louis G. Lange in 2010 and is headquartered in Palo Alto, CA.

Executive Vice President & Chief Financial Officer

2012 - 2020

BioMarin Pharmaceutical, Inc.

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Chief Executive Officer

2009 - 2012

Filtini, Inc.

Boards & Committees

Independent Director

2010 - 2014

Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A nephropathy. The company was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.

Director

2003 - 2006

Xcyte Therapies, Inc.

Xcyte Therapies is a development stage biotech company that develops therapeutic products which enhances the body’s natural immune responses to treat cancer, infectious diseases, and other medical conditions associated with weakened immune systems. Xcyte Therapies is based in the United States and the company was founded in 1996.

Transactions

Details Hidden

BioMarin Pharmaceutical, Inc. issued USD Common Stock

Investments

Details Hidden

Rapidscan Pharma Solutions, Inc.

Rapidscan Pharma Solutions, Inc. provides novel technologies for the diagnosis of disease. Its products include Regadenoson which acts as a stress agent used in the diagnosis and risk stratification of cardiovascular disease. The company was founded by Brent K. Blackburn, Daniel K. Spiegelman and Louis G. Lange in 2010 and is headquartered in Palo Alto, CA.

Public Holdings

Restricted data only for RelSci Professional users.

Events

Speaker

New York City, NY

2013 UBS Global Healthcare Conference

Other Affiliations

Daniel K. Spiegelman is affiliated with Rapidscan Pharma Solutions, Inc., BioMarin Pharmaceutical, Inc., Filtini, Inc., CV Therapeutics, Inc., Genentech, Inc., Anthera Pharmaceuticals, Inc., Xcyte Therapies, Inc.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Daniel K. Spiegelman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Daniel K. Spiegelman's profile does not indicate a business or promotional relationship of any kind between RelSci and Daniel K. Spiegelman.